Octapharma

PRDT's prion capture technology is used at industrial scale by Octapharma AG ( "Octapharma") for the manufacturing of OctaplasLG®.

Marketwire - Breaking News Releases 2010

But having said that, we're really not with inventory right now as a result of the Octapharma situation.

unknown title 2011

This performance continues to reflect the success we've had with our commercial strategies and the benefit related to meeting volume previously served by Octapharma, which for the quarter, was an incremental $30 million to $40 million in sales.

unknown title 2011

David, let me also add, just as we mentioned last quarter that as long as Octapharma is out, there could be periods where there'll be temporary shortages or we'd be in the backorder situation for throughout the rest of this year.

unknown title 2011

You're right, the Octapharma piece that you mentioned, Mike, is in fact part of it, but it's just one of the number of pieces, so I'll let Bob kind of walk you through.

unknown title 2011

I was wondering if you could perhaps just reconcile the additional purchases of plasma with Octapharma as well as some of the third parties with respect to their return trajectory that would seem to imply it's somewhat measured, but I was wondering if you could provide some perspective on that?

unknown title 2011

I think it will be helpful to give a sense of where you think you might be conservative in that forecast as part of it that you're assuming that Octapharma does make some inroads back into the market and that's why you're being a bit conservative.

unknown title 2011

As a reminder, due to year-over-year sales comparisons related to Octapharma, we expect Antibody Therapy sales growth to moderate in the back half of 2011.

unknown title 2011

Our current guidance assumes a modest benefit in the third quarter related to Octapharma as we currently assume that they will return to the U.S. market by the fourth quarter.

unknown title 2011

This outlook includes the first half sales of approximately $60 million related to the U.S. multisource Generic Injectables business and $60 million to $70 million of incremental sales related to Octapharma.

unknown title 2011